<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473977</url>
  </required_header>
  <id_info>
    <org_study_id>2017-1701</org_study_id>
    <nct_id>NCT03473977</nct_id>
  </id_info>
  <brief_title>Benralizumab for Eosinophilic Gastritis (BEGS)</brief_title>
  <acronym>BEGS</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of&#xD;
      Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To assess the efficacy of repeat subcutaneous (SC) doses of benralizumab, compared with&#xD;
      placebo, to reduce eosinophilic inflammation in the gastrointestinal tract of patients with&#xD;
      Eosinophilic Gastritis&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To assess changes in endoscopic score, histological features, blood and biopsy eosinophil&#xD;
      counts, clinical symptoms, and gastric tissue transcriptome before and after treatment with&#xD;
      benralizumab.&#xD;
&#xD;
      26 subjects are planned to be enrolled into the study at Cincinnati Children's Hospital&#xD;
      Medical Center. Qualifying Subjects will receive subcutaneous injections every 4 weeks (3&#xD;
      total) of benralizumab/Placebo, followed by optional Open Label Extension periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Actual">June 22, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will receive doses of drug or placebo. Optional open label extensions available following the double blind period.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant/care providers, investigators, and outcome assessor (pathology) were blinded to assignment. Randomization performed by external investigational pharmacy staff (dispenses the drug/placebo).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patients in Histological Remission (&lt;30 Eos/Hpf)</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
    <description>Percent of patients in histologic remission in drug versus placebo groups. Remission is defined as gastric peak eosinophil count &lt; 30 eosinophils per high powered field (eos/hpf).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Gastric Endoscopic Score (Lanza)</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
    <description>The gastric endoscopic score (Lanza) utilizes standardized criteria for the presence and degree of 5 major endoscopic features (granularity, nodularity, erosion/ulceration, friability, erythema). Total score is the maximum score of the five feature scores from the body, antrum, or fundus. Total scores range from 0 - 14. Change in total endoscopic reference score is defined as post-treatment score minus pre-treatment score. Changes in scores are compared between drug and Placebo. A reduction (negative change) in score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gastric Histology Score</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
    <description>The gastric histology score quantifies inflammatory and structural histologic abnormalities in the stomach. Total score is the sum of features scores divided by the maximum possible score for the biopsy. Features include lamina propria eosinophil sheets, periglandular circumferential collars, eosinophils in surface epithelium, eosinophil glandulitis, eosinophil gland abscesses, eosinophils in muscularis mucosa, lamina propria fibroplasia, lamina propria smooth muscle hyperplasia, reactive epithelial changes, acute inflammatory cells, and surface erosion. Total scores range from 0 - 1. Change in gastric total histology scoring is defined as post-treatment total score minus pretreatment total score. Changes in scores are compared between drug and placebo. A reduction (negative change) in score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Eosinophil Count</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
    <description>Change in absolute eosinophil counts (cells per microliter) is defined as post treatment counts minus pre-treatment counts. Changes in counts are compared between drug and Placebo. A decrease in count is expected due to the effects of the drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eosinophilic Gastritis Diagnostic Panel</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
    <description>The transcriptomic signature of gastric biopsy samples was obtained using real-time polymerase chain reaction amplification on the EG diagnostic panel (EGDP) comprising a set of 48 gastric transcripts. The EGDP value was calculated by summing delta CT (threshold cycle) values of the most highly dysregulated genes. Change is defined as post treatment value minus pre-treatment value. An increase (positive change) indicates improvement (normalization of gene expression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gastric Peak Eosinophil Count</measure>
    <time_frame>12 weeks after starting treatment</time_frame>
    <description>Change in gastric peak eosinophil count is defined as post-treatment peak count minus pre-treatment peak count. Changes in peak count are compared between Drug and Placebo. A reduction (negative change) in peak count indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Symptoms</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
    <description>The symptom of dyspepsia (SODA) questionnaire captures symptoms associated with gastric dyspepsia including symptoms associated with &quot;pain&quot; and &quot;non-pain&quot; as well as general &quot;satisfaction&quot; with present symptoms. The scores range from 0 to 47 for pain; 0 to 35 for non-pain, and 0 to 23 for satisfaction. Higher scores indicate more frequent and/or severe symptoms for pain and non-pain. Higher scores indicate greater Satisfaction. Change in score is defined as post-treatment total score minus pre-treatment total score. A reduction (negative change) indicates improvement in pain and non-pain. An increase (positive change) indicates improvement in satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Eosinophilic Gastritis or Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Benralizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous dose of Placebo every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.</description>
    <arm_group_label>Benralizumab</arm_group_label>
    <other_name>Fasenra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent: Able to give written informed consent prior to participation in the&#xD;
             study, which will include the ability to comply with the requirements and restrictions&#xD;
             listed in the consent form. Subjects must be able to read, comprehend, and write at a&#xD;
             level sufficient to complete study related materials.&#xD;
&#xD;
          -  Males and females between the ages of 12-60 years with confirmed diagnosis of EG&#xD;
             involving stomach; involvement of eosinophilic inflammation in other gastrointestinal&#xD;
             segments will be allowed but not required or sufficient.&#xD;
&#xD;
          -  Histologically active EG at time of screening, with a peak Gastric count of ≥ 30&#xD;
             eos/hpf in at least 5 hpfs.&#xD;
&#xD;
          -  Must be symptomatic (defined as having experienced symptoms within 4 weeks prior to&#xD;
             enrollment).&#xD;
&#xD;
          -  Blood eosinophilia (defined as having an absolute eosinophil count &gt; 500 cells per&#xD;
             microliter of blood) at least once during the 6 months prior to enrollment.&#xD;
&#xD;
          -  Must be on baseline anti-eosinophilic gastritis/eosinophilic gastroenteritis therapy&#xD;
             as long as there is agreement to not change their dosage unless medically indicated;&#xD;
             OR, must have failed anti-eosinophilic gastritis/eosinophilic gastroenteritis in the&#xD;
             past, including diet therapy.&#xD;
&#xD;
          -  Clinical symptoms (i.e., abdominal pain, bloating, vomiting, diarrhea) severe enough&#xD;
             to impact daily life (e.g., school/work attendance, social activities) ≥ 2 days/week&#xD;
             for 3 of the 4 weeks prior to enrollment despite treatment (such as diet, proton pump&#xD;
             inhibitors or corticosteroids).&#xD;
&#xD;
          -  Female subjects: Women of childbearing potential (WOCBP) must use an effective form of&#xD;
             birth control (confirmed by the Investigator). Effective forms of birth control&#xD;
             include: true sexual abstinence, a vasectomized sexual partner, Implanon, female&#xD;
             sterilization by tubal occlusion, any effective intrauterine device/ levonogestrel&#xD;
             Intrauterine system, Depo-Provera(tm) injections, oral contraceptive, and Evra&#xD;
             Patch(tm) or Nuvaring(tm). WOCBP must agree to use effective method of birth control,&#xD;
             as defined above, from enrollment, throughout the study duration and within 16 weeks&#xD;
             after last dose of investigational product, and have negative serum pregnancy test&#xD;
             result on Visit 1.&#xD;
&#xD;
          -  Women not of childbearing potential are defined as women who are either permanently&#xD;
             sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who&#xD;
             are postmenopausal. Women will be considered postmenopausal if they have been&#xD;
             amenorrheic for 12 months prior to the planned date of visit -1 without an alternative&#xD;
             medical cause. The following age-specific requirements apply:&#xD;
&#xD;
          -  Women &lt;50 years old would be considered postmenopausal if they have been amenorrheic&#xD;
             for 12 months or more following cessation of exogenous hormonal treatment and follicle&#xD;
             stimulating hormone (FSH) levels in the postmenopausal range.&#xD;
&#xD;
          -  Women ≥50 years old would be considered postmenopausal if they have been amenorrheic&#xD;
             for 12 months or more following cessation of all exogenous hormonal treatment.&#xD;
&#xD;
          -  All male subjects who are sexually active must agree to use an acceptable method of&#xD;
             contraception (condom with or without spermicide, vasectomy) from Visit 1 until 16&#xD;
             weeks after their last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent H. pylori gastritis or parasitic infection&#xD;
&#xD;
          -  Other gastrointestinal disorders such as Crohn's disease, inflammatory bowel disease,&#xD;
             or Celiac disease, eosinophilic granulomatosis with polyangiitis (EGPA), drug&#xD;
             hypersensitivity or connective tissue rheumatological disorders,&#xD;
&#xD;
          -  Esophageal stricture that prevents the easy passage of a standard endoscope&#xD;
&#xD;
          -  Use of any investigational biologic drug within 6 months prior to screening&#xD;
&#xD;
          -  Hypereosinophilic syndrome, defined by multiple organ involvement (with the exception&#xD;
             of atopic disease or EGID) and persistent blood absolute eosinophil count ≥1500/mcL.&#xD;
&#xD;
          -  History of cancer: Subjects who have had basal cell carcinoma, localized squamous cell&#xD;
             carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that&#xD;
             the subject is in remission and curative therapy was completed at least 12 months&#xD;
             prior to the date informed consent, and assent when applicable was obtained. Subjects&#xD;
             who have had other malignancies are eligible provided that the subject is in remission&#xD;
             and curative therapy was completed at least 5 years prior to the date informed&#xD;
             consent, and assent when applicable, was obtained.&#xD;
&#xD;
          -  A helminth parasitic infection diagnosed within 24 weeks prior to the date informed&#xD;
             consent is obtained that has not been treated with, or has failed to respond to&#xD;
             standard of care therapy.&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Receipt of any investigational non-biologic within 30 days or 5 half-lives prior to&#xD;
             visit 1, whichever is longer.&#xD;
&#xD;
          -  A history of known immunodeficiency disorder including a positive human&#xD;
             immunodeficiency virus (HIV) test.&#xD;
&#xD;
          -  Any other medical illness that precludes study involvement&#xD;
&#xD;
          -  Positive hepatitis B surface antigen, or hepatitis C virus antibody serology, or a&#xD;
             positive medical history for hepatitis B or C. Subjects with a history of hepatitis B&#xD;
             vaccination without history of hepatitis B are allowed to be enrolled.&#xD;
&#xD;
          -  Patients who are currently receiving or have previously received benralizumab or any&#xD;
             other type of anti-interleukin therapy (i.e. mepolizumab, reslizumab, lebrikizumab&#xD;
             etc.) within the last 6 months or 5 half-lives whichever is longer.&#xD;
&#xD;
          -  History of anaphylaxis to any biologic therapy or vaccine.&#xD;
&#xD;
          -  Receipt of immunoglobulin or blood products within 30 days prior to the date informed&#xD;
             consent is obtained.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc E Rothenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <results_first_submitted>June 21, 2021</results_first_submitted>
  <results_first_submitted_qc>July 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2021</results_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
    <mesh_term>Enteritis</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03473977/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from an eosinophilic disorder specialty clinic in the US between April 2018 and January 2020.</recruitment_details>
      <pre_assignment_details>34 participants screened, 8 excluded (8 did not meet inclusion criteria), and 26 randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Benralizumab</title>
          <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks&#xD;
Benralizumab: Benralizumab (anti-IL5Ra) will be injected in doses of 30 mg every 4 weeks (3 times) in subjects with active Eosinophilic Gastritis.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subcutaneous dose of Placebo every 4 weeks&#xD;
Placebo: Placebo will be injected every 4 weeks (3 times) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Benralizumab</title>
          <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks (total of 3 doses)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subcutaneous dose of Placebo every 4 weeks (total of 3 doses)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.9" spread="2.0"/>
                    <measurement group_id="B2" value="24.1" spread="7.9"/>
                    <measurement group_id="B3" value="19.5" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gastric Peak Eosinophil Count</title>
          <description>Maximum eosinophil count (eosinophils per high power field) in gastric biopsies</description>
          <units>eosinophils per high power field</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210" lower_limit="93" upper_limit="230"/>
                    <measurement group_id="B2" value="147" lower_limit="119" upper_limit="208"/>
                    <measurement group_id="B3" value="157" lower_limit="93" upper_limit="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gastric Histology Score</title>
          <description>Gastric histology score quantifies inflammatory and structural histologic features. Total score is the sum of features scores divided by the maximum possible score. Features include lamina propria eosinophil sheets, periglandular circumferential collars, eosinophils in surface epithelium, eosinophil glandulitis, eosinophil gland abscesses, eosinophils in muscularis mucosa, lamina propria fibroplasia, lamina propria smooth muscle hyperplasia, reactive epithelial changes, acute inflammatory cells, and surface erosion. Scores range from 0 - 1. Higher scores indicate more severe abnormalities.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.55" lower_limit="0.50" upper_limit="0.64"/>
                    <measurement group_id="B2" value="0.50" lower_limit="0.45" upper_limit="0.59"/>
                    <measurement group_id="B3" value="0.50" lower_limit="0.45" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gastric Endoscopy Score (Lanza)</title>
          <description>The gastric endoscopy score (Lanza) utilizes standardized criteria for the presence and degree of 5 major endoscopic features (granularity, nodularity, erosion/ulceration, friability, erythema). Total score is the maximum score of the five feature scores from the body, antrum, or fundus. Total scores range from 0 - 14. Higher scores indicate more severe endoscopic findings.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="3.0" upper_limit="5.0"/>
                    <measurement group_id="B2" value="6.0" lower_limit="5.0" upper_limit="8.0"/>
                    <measurement group_id="B3" value="5.0" lower_limit="4.0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Eosinophil Count</title>
          <description>Blood absolute eosinophil counts (cell per microliter)</description>
          <units>cells per microliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1100" lower_limit="830" upper_limit="2610"/>
                    <measurement group_id="B2" value="1640" lower_limit="710" upper_limit="2800"/>
                    <measurement group_id="B3" value="1350" lower_limit="710" upper_limit="2630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SODA Pain Intensity</title>
          <description>The symptom of dyspepsia (SODA) questionnaire captures symptoms associated with gastric dyspepsia including symptoms associated with &quot;pain&quot; . Scores range from 0 to 47 for pain. Higher scores indicate more frequent and/or severe symptoms for pain.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="20" upper_limit="30"/>
                    <measurement group_id="B2" value="27" lower_limit="20" upper_limit="30"/>
                    <measurement group_id="B3" value="26" lower_limit="20" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SODA Non-Pain Symptoms</title>
          <description>The symptom of dyspepsia (SODA) questionnaire captures symptoms associated with gastric dyspepsia including symptoms associated with &quot;non-pain&quot; . The scores range from 0 to 35 for non-pain. Higher scores indicate more frequent and/or severe symptoms.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="13" upper_limit="17"/>
                    <measurement group_id="B2" value="15.5" lower_limit="13" upper_limit="17"/>
                    <measurement group_id="B3" value="16" lower_limit="13" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SODA Satisfaction</title>
          <description>The symptom of dyspepsia (SODA) questionnaire captures general satisfaction associated with present symptoms. The scores range 0 to 23. Higher scores indicate greater Satisfaction.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="B2" value="8" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="B3" value="9" lower_limit="7" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EG Diagnostic Panel</title>
          <description>The transcriptomic signature of gastric biopsy samples was obtained using real-time polymerase chain reaction amplification on the Eosinophilic gastritis diagnostic panel (EGDP) comprising a set of 48 gastric transcripts. The EGDP value was calculated by summing the delta CT (threshold cycle) values of the most highly dysregulated genes. Higher values indicate normalization of the transcriptome.</description>
          <population>Biopsies for gene expression analysis were not collected or failed to yield quality RNA for some subjects</population>
          <units>delta threshold cycle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-58" spread="23"/>
                    <measurement group_id="B2" value="-51" spread="40"/>
                    <measurement group_id="B3" value="-55" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients in Histological Remission (&lt;30 Eos/Hpf)</title>
        <description>Percent of patients in histologic remission in drug versus placebo groups. Remission is defined as gastric peak eosinophil count &lt; 30 eosinophils per high powered field (eos/hpf).</description>
        <time_frame>12 weeks after start of treatment</time_frame>
        <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab</title>
            <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks (total of 3 injections)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous dose of Placebo every 4 weeks (total of 3 injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients in Histological Remission (&lt;30 Eos/Hpf)</title>
          <description>Percent of patients in histologic remission in drug versus placebo groups. Remission is defined as gastric peak eosinophil count &lt; 30 eosinophils per high powered field (eos/hpf).</description>
          <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gastric Endoscopic Score (Lanza)</title>
        <description>The gastric endoscopic score (Lanza) utilizes standardized criteria for the presence and degree of 5 major endoscopic features (granularity, nodularity, erosion/ulceration, friability, erythema). Total score is the maximum score of the five feature scores from the body, antrum, or fundus. Total scores range from 0 - 14. Change in total endoscopic reference score is defined as post-treatment score minus pre-treatment score. Changes in scores are compared between drug and Placebo. A reduction (negative change) in score indicates improvement.</description>
        <time_frame>12 weeks after start of treatment</time_frame>
        <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab</title>
            <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks (total of 3 injections)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous dose of Placebo every 4 weeks (total of 3 injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gastric Endoscopic Score (Lanza)</title>
          <description>The gastric endoscopic score (Lanza) utilizes standardized criteria for the presence and degree of 5 major endoscopic features (granularity, nodularity, erosion/ulceration, friability, erythema). Total score is the maximum score of the five feature scores from the body, antrum, or fundus. Total scores range from 0 - 14. Change in total endoscopic reference score is defined as post-treatment score minus pre-treatment score. Changes in scores are compared between drug and Placebo. A reduction (negative change) in score indicates improvement.</description>
          <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gastric Histology Score</title>
        <description>The gastric histology score quantifies inflammatory and structural histologic abnormalities in the stomach. Total score is the sum of features scores divided by the maximum possible score for the biopsy. Features include lamina propria eosinophil sheets, periglandular circumferential collars, eosinophils in surface epithelium, eosinophil glandulitis, eosinophil gland abscesses, eosinophils in muscularis mucosa, lamina propria fibroplasia, lamina propria smooth muscle hyperplasia, reactive epithelial changes, acute inflammatory cells, and surface erosion. Total scores range from 0 - 1. Change in gastric total histology scoring is defined as post-treatment total score minus pretreatment total score. Changes in scores are compared between drug and placebo. A reduction (negative change) in score indicates improvement.</description>
        <time_frame>12 weeks after start of treatment</time_frame>
        <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab</title>
            <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks (total of 3 injections)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous dose of Placebo every 4 weeks (total of 3 injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gastric Histology Score</title>
          <description>The gastric histology score quantifies inflammatory and structural histologic abnormalities in the stomach. Total score is the sum of features scores divided by the maximum possible score for the biopsy. Features include lamina propria eosinophil sheets, periglandular circumferential collars, eosinophils in surface epithelium, eosinophil glandulitis, eosinophil gland abscesses, eosinophils in muscularis mucosa, lamina propria fibroplasia, lamina propria smooth muscle hyperplasia, reactive epithelial changes, acute inflammatory cells, and surface erosion. Total scores range from 0 - 1. Change in gastric total histology scoring is defined as post-treatment total score minus pretreatment total score. Changes in scores are compared between drug and placebo. A reduction (negative change) in score indicates improvement.</description>
          <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-0.41" upper_limit="-0.27"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.10" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Eosinophil Count</title>
        <description>Change in absolute eosinophil counts (cells per microliter) is defined as post treatment counts minus pre-treatment counts. Changes in counts are compared between drug and Placebo. A decrease in count is expected due to the effects of the drug.</description>
        <time_frame>12 weeks after start of treatment</time_frame>
        <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab</title>
            <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks (total of 3 injections)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous dose of Placebo every 4 weeks (total of 3 injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Eosinophil Count</title>
          <description>Change in absolute eosinophil counts (cells per microliter) is defined as post treatment counts minus pre-treatment counts. Changes in counts are compared between drug and Placebo. A decrease in count is expected due to the effects of the drug.</description>
          <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
          <units>cells per microliter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1060" lower_limit="-1740" upper_limit="-830"/>
                    <measurement group_id="O2" value="-160" lower_limit="-710" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Eosinophilic Gastritis Diagnostic Panel</title>
        <description>The transcriptomic signature of gastric biopsy samples was obtained using real-time polymerase chain reaction amplification on the EG diagnostic panel (EGDP) comprising a set of 48 gastric transcripts. The EGDP value was calculated by summing delta CT (threshold cycle) values of the most highly dysregulated genes. Change is defined as post treatment value minus pre-treatment value. An increase (positive change) indicates improvement (normalization of gene expression).</description>
        <time_frame>12 weeks after start of treatment</time_frame>
        <population>Includes participants with pre and post-treatment samples</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab</title>
            <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks (total of 3 injections)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous dose of Placebo every 4 weeks (total of 3 injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Eosinophilic Gastritis Diagnostic Panel</title>
          <description>The transcriptomic signature of gastric biopsy samples was obtained using real-time polymerase chain reaction amplification on the EG diagnostic panel (EGDP) comprising a set of 48 gastric transcripts. The EGDP value was calculated by summing delta CT (threshold cycle) values of the most highly dysregulated genes. Change is defined as post treatment value minus pre-treatment value. An increase (positive change) indicates improvement (normalization of gene expression).</description>
          <population>Includes participants with pre and post-treatment samples</population>
          <units>delta threshold cycle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="31"/>
                    <measurement group_id="O2" value="-12" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gastric Peak Eosinophil Count</title>
        <description>Change in gastric peak eosinophil count is defined as post-treatment peak count minus pre-treatment peak count. Changes in peak count are compared between Drug and Placebo. A reduction (negative change) in peak count indicates improvement.</description>
        <time_frame>12 weeks after starting treatment</time_frame>
        <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab</title>
            <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks (total of 3 injections)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous dose of Placebo every 4 weeks (total of 3 injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gastric Peak Eosinophil Count</title>
          <description>Change in gastric peak eosinophil count is defined as post-treatment peak count minus pre-treatment peak count. Changes in peak count are compared between Drug and Placebo. A reduction (negative change) in peak count indicates improvement.</description>
          <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
          <units>eosinophils per high power field</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-132" lower_limit="-196" upper_limit="-82"/>
                    <measurement group_id="O2" value="-29" lower_limit="-89" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Symptoms</title>
        <description>The symptom of dyspepsia (SODA) questionnaire captures symptoms associated with gastric dyspepsia including symptoms associated with &quot;pain&quot; and &quot;non-pain&quot; as well as general &quot;satisfaction&quot; with present symptoms. The scores range from 0 to 47 for pain; 0 to 35 for non-pain, and 0 to 23 for satisfaction. Higher scores indicate more frequent and/or severe symptoms for pain and non-pain. Higher scores indicate greater Satisfaction. Change in score is defined as post-treatment total score minus pre-treatment total score. A reduction (negative change) indicates improvement in pain and non-pain. An increase (positive change) indicates improvement in satisfaction.</description>
        <time_frame>12 weeks after start of treatment</time_frame>
        <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Benralizumab</title>
            <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks (total of 3 injections)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subcutaneous dose of Placebo every 4 weeks (total of 3 injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Symptoms</title>
          <description>The symptom of dyspepsia (SODA) questionnaire captures symptoms associated with gastric dyspepsia including symptoms associated with &quot;pain&quot; and &quot;non-pain&quot; as well as general &quot;satisfaction&quot; with present symptoms. The scores range from 0 to 47 for pain; 0 to 35 for non-pain, and 0 to 23 for satisfaction. Higher scores indicate more frequent and/or severe symptoms for pain and non-pain. Higher scores indicate greater Satisfaction. Change in score is defined as post-treatment total score minus pre-treatment total score. A reduction (negative change) indicates improvement in pain and non-pain. An increase (positive change) indicates improvement in satisfaction.</description>
          <population>Intent to treat analysis including participants who had at least one clinical observation post randomization.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="-9.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-6.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-pain score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-4.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-3.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pain Score Comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-pain score comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Satisfaction score comparison</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From informed consent to 4 weeks after the end of the 12 week double-blind. On average, this was approximately 20 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Benralizumab</title>
          <description>Subcutaneous dose of 30 mg of Benralizumab every 4 weeks (total of 3 doses)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subcutaneous dose of Placebo every 4 weeks (total of 3 doses)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Belching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bacterial overgrowth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flu-like Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Strep Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Parasthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sensitive skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc E. Rothenberg, MD, PhD</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>513-636-7177</phone>
      <email>marc.rothenberg@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

